Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma

Cancer
Alexander BuchnerRalph Oberneder

Abstract

The prognostic relevance of disseminated cytokeratin-positive (CK+) tumor cells in the bone marrow of patients with different types of carcinoma has been demonstrated in several studies. In this prospective study, the frequency and prognostic value of CK+ tumor cells was investigated in the bone marrow of 55 consecutive patients with metastatic renal cell carcinoma (M1 RCC) in comparison with 256 M0 RCC patients from a previous study. Aspiration of bone marrow from the anterior iliac crest was performed immediately before tumor resection in RCC patients. Cytospins were made and stained by immunocytochemistry using the APAAP (alkaline phosphatase-antialkaline phosphatase) protocol and monoclonal antibodies CK2 and A45-B/B3. Twenty-seven patients with no evidence of any malignant disease served as a control group. CK+ tumor cells were detected in 42% (23 of 55 patients) of the M1 patients and 25% (63 of 256 patients) of the M0 patients (P <.01). No CK+ cells (0 of 27 patients) were detected in the control group. In the M1 group, CK- patients demonstrated a trend toward a better outcome compared with CK+ patients (log-rank test, P = .19). This difference was significant when applying a higher threshold (0-2 CK+ cells vs. > or = 3 ...Continue Reading

References

May 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G SchlimokG Riethmüller
Feb 1, 1984·The Journal of Histochemistry and Cytochemistry : Official Journal of the Histochemistry Society·J L CordellD Y Mason
Sep 19, 1996·The New England Journal of Medicine·R J MotzerD M Nanus
Feb 20, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·I Funke, W Schraut
Jul 7, 1999·Journal of the National Cancer Institute·K PantelO Fodstad
Mar 30, 2002·Nature Biotechnology·Christoph A KleinGert Riethmüller
Sep 21, 2002·Lancet·Christoph A KleinGert Riethmüller
Jun 17, 2003·Proceedings of the National Academy of Sciences of the United States of America·Oleg Schmidt-KittlerChristoph A Klein

❮ Previous
Next ❯

Citations

Nov 6, 2007·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Thomas HofmannRainer Riesenberg
Apr 20, 2007·BJU International·Jeffrey S TurnerDavid I Quinn
Aug 27, 2011·Advances in Urology·Stephan KruckArnulf Stenzl
Nov 12, 2020·International Journal of Molecular Sciences·Takuya OwariHiroki Kuniyasu
Aug 15, 2006·Current Opinion in Urology

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.